Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
NASDAQ:CYTO
Price:
1.416 USD
-5.6%
Market Closed
Updated:
May 10, 2024
Altamira Therapeutics Ltd
Net Income (Common)
|
Altamira Therapeutics Ltd
Net Income (Common) Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Net Income (Common)
-CHf3.9m
|
CAGR 3-Years
22%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Net Income (Common)
$17.5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Net Income (Common)
-$16.5m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Net Income (Common)
CHf11.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Net Income (Common)
$848m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Altamira Therapeutics Ltd's Net Income (Common)?
Net Income (Common)
-3.9m
CHF
-3.9m
CHF
Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Net Income (Common) amounts to -3.9m CHF.
What is Altamira Therapeutics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
20%
20%
Over the last year, the Net Income (Common) growth was 85%. The average annual Net Income (Common) growth rates for Altamira Therapeutics Ltd have been 22% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
